Beranda › Kanker Paru Non-Sel Kecil › California › Mountain View
Uji klinis Kanker Paru Non-Sel Kecil di Mountain View, CA
21 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Mountain View (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Menerima pesertaFase 1/2
- Stanford Cancer Institute (Melanoma/NSCLC), Stanford · 5 mi jauhnya
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi jauhnya
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 mi jauhnya
Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
Menerima pesertaFase 3
- Stanford University, Stanford · 5 mi jauhnya
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Menerima pesertaFase 2
- Stanford Cancer Institute, Stanford · 5 mi jauhnya
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Menerima pesertaStudi observasional
- Stanford University, Palo Alto · 5 mi jauhnya
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Menerima pesertaFase 2
- Stanford Cancer Institute, Stanford · 5 mi jauhnya
- Stanford Hospital and Clinics, Stanford · 5 mi jauhnya
- Stanford Hospital Investigational Drug Services, Stanford · 5 mi jauhnya
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Stanford Cancer Center, Palo Alto · 5 mi jauhnya
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- Stanford Cancer Institute, Stanford · 5 mi jauhnya
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Menerima pesertaFase 1/2
- Stanford University Medical Center - Neurology, Stanford · 5 mi jauhnya
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Palo Alto Medical Foundation Research Center, Palo Alto · 5 mi jauhnya
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 1/2
- Stanford Cancer Institute, Stanford · 5 mi jauhnya
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Menerima pesertaFase 1/2
- Stanford University Medical Center, Stanford · 5 mi jauhnya
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Menerima pesertaFase 1
- Stanford University Medical Center, Palo Alto · 5 mi jauhnya
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Menerima pesertaFase 1
- Stanford University, Palo Alto · 5 mi jauhnya
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Menerima pesertaFase 1/2
- Stanford University - Stanford Cancer Institute, Stanford · 5 mi jauhnya
A Study of LY4175408 in Participants With Advanced Cancer
Menerima pesertaFase 1
- Stanford Medicine Cancer Center, Stanford · 5 mi jauhnya
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Menerima pesertaFase 1/2
- Stanford University, Stanford · 5 mi jauhnya
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Menerima pesertaFase 1/2
- Stanford Women's Cancer Center, Palo Alto · 5 mi jauhnya
Engagement of Veterans With Lung Cancer
Menerima peserta
- Veterans Affairs Palo Alto Health Care System (VAPAHCS), Palo Alto · 5 mi jauhnya
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Stanford · 5 mi jauhnya
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Menerima pesertaFase 1
- Stanford University, Stanford · 5 mi jauhnya
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Studi lain di Mountain View
- Kanker (semua jenis)40 studi
- Kanker Payudara26 studi
- Kanker Metastatik25 studi
- Leukemia Mieloid Akut19 studi
- Kanker Ovarium19 studi
- Gangguan Spektrum Autisme17 studi
- Kanker Paru17 studi
- Kanker Prostat15 studi
- Gagal Jantung15 studi
- Autisme13 studi
- Leukemia Limfoblastik Akut13 studi
- Kanker Kolorektal13 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.